AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2022
Oct 4, 2022
32883_dirs_2022-10-03_417b7543-87d7-4977-9b5d-267a1eca8164.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-09-30
Reporting Person: Anderson Raymond (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-09-30 | Common Stock | M | 2859 | — | Acquired | 13871 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | Restricted Stock Units | $ | M | 2859 | Disposed | Common Stock (2859) | Direct |
Footnotes
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.